Instruction 1(b).

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMM Washington, D.C. 20549

ISSION	
	OMB

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response.. 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Dunne Michael W.			2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(First) (Middle) C/O ITERUM THERAPEUTICS PLC, BLK 2, FL. 3, HARCOURT CENTRE, HARCOURT ST.			3. Date of Earliest Transaction (Month/Day/Year) 10/27/2020						X Officer (give title below) Other (specify below) Chief Scientific Officer						
(Street) DUBLIN, L2 2			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu						Acquire	uired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea) Ordinary Shares 10/27/2020			Execut any		(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(D) O Ti	wned Followi ransaction(s)			Ownership Form:	7. Nature of Indirect Beneficial	
			(Montl	h/Day/Year)	Coo	de V	Amount (A) or (D)		(In	Instr. 3 and 4)			Direct (D) (or Indirect (I) (Instr. 4)	Ownership Instr. 4)	
			10/27/2020			P	,	61,540	A	<u>(1)</u> 20	209,498			D	
	Report on a s	eparate line for each	class of securities be	eneficial	ly owned dii	rectly o	Perso in this	ns who form a	re not red	quired t	collection of to respond u				474 (9-02)
	Report on a se	eparate line for each		· Derivat	tive Securiti	ies Acq	Perso in this a curr uired, Disp	ns who form a ently va	re not red lid OMB or Benefi	quired to control cially O	o respond u number.				474 (9-02)
Reminder: R 1. Title of Derivative Security	2. Conversion	3. Transaction	Table II -	Derivat (e.g., pu 4. Transac Code	tive Securiti tts, calls, wa 5. Nun of Deri Securit	hber ivative ties ed (A)	Perso in this a curr quired, Dispositions, contions, con	ns who form a ently va osed of, onvertib ercisable Date	re not red lid OMB or Benefi de securit	quired to control cially Ovices)	orespond unumber. wned and Amount erlying ies	8. Price of		f 10. Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Natu p of Indire Benefic e Owners (Instr. 4
Reminder: R 1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transac Code	tive Securiti tts, calls, wa 5. Nun of Deri Securit O Dist of (D) (Instr.	hber ivative ties ed (A)	Perso in this a curr quired, Disp , options, c	ns who form a ently va cosed of, onvertibe ercisable Date y/Year)	re not rec lid OMB or Benefi le securiti and	cially Ories) 7. Title of Under Securiti	orespond unumber. wned and Amount erlying ies	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Natu p of Indire Benefic e Owners (Instr. 4

reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Dunne Michael W. C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2			Chief Scientific Officer			

Signatures

s/s Michael W. Dunne	10/28/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported securities were purchased in the Issuer's registered public offering on October 27, 2020 at a combined purchase price of \$0.65 per ordinary share and warrant. Each ordinary share was purchased together with a warrant to purchase 0.75 of an ordinary share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.